Aytu Biopharma, Inc.
AYTU
$2.18
$0.010.46%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -329.24% | 238.34% | 458.18% | 118.15% | -87.91% |
| Total Depreciation and Amortization | -16.94% | -14.09% | -25.24% | -22.57% | -26.37% |
| Total Amortization of Deferred Charges | -80.60% | -83.23% | -81.82% | -81.76% | -76.03% |
| Total Other Non-Cash Items | 448.35% | -108.05% | -193.69% | -139.60% | -46.57% |
| Change in Net Operating Assets | 218.51% | -690.24% | 171.81% | 67.92% | -158.46% |
| Cash from Operations | 455.71% | -2,441.34% | 2,251.85% | -463.98% | -108.41% |
| Capital Expenditure | 94.83% | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1,116.95% | -- | -- | -- | 290.32% |
| Cash from Investing | -8,773.53% | -53.33% | 183.33% | 601.32% | 78.06% |
| Total Debt Issued | -93.54% | 33,322.22% | -- | -- | 309.62% |
| Total Debt Repaid | 97.04% | -190.63% | -119.34% | -25.41% | -588.61% |
| Issuance of Common Stock | 338.92% | -- | -- | -- | 31.92% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -378.95% | -- | -- | 78.85% | -153.01% |
| Cash from Financing | 1,116.57% | 711.13% | -2,090.48% | 133.32% | 119.76% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 5,094.72% | -1,063.20% | 166.67% | 103.38% | -93.54% |